Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

NCT01714726 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: MEDI2070
DRUG: placebo

Sponsor

AstraZeneca

Collaborators

[object Object]